MLAB on Nasdaq
MESA LABORATORIES INC /CO/
American industrial instruments for measurement company based in Lakewood.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with HURCO COMPANIES INC, SYPRIS SOLUTIONS INC or Cognex Corporation, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
63.5%Gross margin2
7.4%Operating margin2
2.7%Net margin2
3.4%Revenue growth, 20262
3.6%Return on equity2
0.36×Debt to equity2
$39.6MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 82% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2024 | 2025 | 2026 |
|---|---|---|---|
| Product | $176.8M | $198.4M | $203.4M |
| Service | $39.4M | $42.6M | $45.7M |
Business segments
Sterilization and Disinfection Control brought in 41% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Business segments by year
| Business segments | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sterilization and Disinfection Control | $75.1M | $93.4M | $101.6M |
| Calibration Solutions | $47.8M | $51.7M | $53.6M |
| Biopharmaceutical Development | $40.7M | $48.7M | $48.6M |
| Clinical Genomics | $52.6M | $47.1M | $45.4M |
Regions
United States brought in 47% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Regions by year
| Regions | 2024 | 2025 | 2026 |
|---|---|---|---|
| United States | $106.4M | $116.6M | $116.9M |
| Other | $84.9M | $99.1M | $111.8M |
| [China [Member]] | $24.9M | $25.3M | $20.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue36¢$90.9M
- Research and development8¢$20.3M
- Other costs51¢$125.9M
- Income tax2¢$5.3M
- Profit3¢$6.7M
Out of $249.1M in revenue.2
Where each dollar of operating cash went, fiscal 2026
- Capital spending8¢$3.2M
- Dividends paid8¢$3.5M
- Kept or used elsewhere84¢$36.1M
Out of $42.8M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Revenue | $249.1M | $241.0M | $216.2M |
| Cost of revenue | $90.9M | $90.1M | $82.9M |
| Gross profit | $158.3M | $150.9M | $133.2M |
| Selling | $40.8M | $41.7M | $38.6M |
| General and administrative, other than impairment of finite-lived intangible assets and goodwill | $78.7M | $73.3M | $72.9M |
| Research and development | $20.3M | $19.5M | $19.3M |
| Impairment of finite-lived intangible assets | $0 | $0 | $117.6M |
| Impairment of goodwill | $0 | $0 | $156.9M |
| Total operating expense | $139.8M | $134.5M | $405.3M |
| Operating income (loss) | $18.5M | $16.3M | -$272.1M |
| Interest expense and amortization of debt issuance costs | $10.7M | $11.9M | $5.7M |
| Gain on extinguishment of convertible senior notes | $0 | -$2.9M | $0 |
| Other (income) expense, net | -$4.2M | $1.4M | -$2.1M |
| Total nonoperating expense, net | $6.5M | $10.4M | $3.6M |
| Earnings (loss) before income taxes | $12.0M | $6.0M | -$275.6M |
| Income tax expense (benefit) | $5.3M | $7.9M | -$21.4M |
| Net income (loss) | $6.7M | -$2.0M | -$254.2M |
| Basic earnings (loss) per share (in dollars per share) | $1.22 | -$0.36 | -$47.20 |
| Diluted earnings (loss) per share (in dollars per share) | $1.21 | -$0.36 | -$47.20 |
| Basic (in shares) | 5.5M shares | 5.4M shares | 5.4M shares |
| Diluted (in shares) | 5.6M shares | 5.4M shares | 5.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $26.9M | $27.3M | ||
| Accounts receivable, less allowances for credit losses of $2,569 and $1,186, respectively | $44.1M | $42.0M | ||
| Inventories | $26.4M | $25.4M | ||
| Prepaid expenses and other current assets | $8.9M | $8.0M | ||
| Total current assets | $106.3M | $102.7M | ||
| Property, plant and equipment, net | $30.6M | $32.3M | ||
| Deferred tax asset | $1.5M | $1.4M | ||
| Other Assets, Noncurrent | $19.2M | $18.3M | ||
| Intangible assets | $83.3M | $96.9M | ||
| Goodwill | $186.9M | $181.8M | $180.1M | |
| Total assets | $427.7M | $433.3M | ||
| Accounts payable | $4.9M | $5.7M | ||
| Accrued payroll and benefits | $19.0M | $17.9M | ||
| Unearned revenues | $14.7M | $14.7M | ||
| Other accrued expenses | $17.6M | $24.6M | ||
| Term loan, current portion | $5.6M | $3.8M | ||
| Convertible senior notes, current portion, net of debt issuance costs | $0 | $97.3M | ||
| Total current liabilities | $61.9M | $164.0M | ||
| Deferred tax liability | $20.1M | $20.2M | ||
| Other Liabilities, Noncurrent | $13.7M | $12.5M | ||
| Noncurrent portion | $61.4M | $66.9M | ||
| Revolving line of credit | $84.5M | $10.0M | ||
| Total liabilities | $241.5M | $273.5M | ||
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,931 and 5,455,421 shares, respectively | $375.3M | $358.5M | ||
| (Accumulated deficit) | -$185.7M | -$188.9M | ||
| Accumulated other comprehensive (loss) | -$3.4M | -$9.8M | ||
| Total stockholders equity | $186.2M | $159.8M | $145.4M | $393.5M |
| Total liabilities and stockholders equity | $427.7M | $433.3M | ||
| Allowance for doubtful accounts receivable | $2.6M | $1.2M | ||
| Common stock, no par value (in dollars per share) | $0 | $0 | ||
| Common stock, authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Common stock, issued (in shares) | 5.5M shares | 5.5M shares | ||
| Common stock, outstanding (in shares) | 5.5M shares | 5.5M shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $26.9M | $27.3M | ||
| Accounts receivable, less allowances for credit losses of $2,569 and $1,186, respectively | $44.1M | $42.0M | ||
| Inventories | $26.4M | $25.4M | ||
| Prepaid expenses and other current assets | $8.9M | $8.0M | ||
| Total current assets | $106.3M | $102.7M | ||
| Property, plant and equipment, net | $30.6M | $32.3M | ||
| Deferred tax asset | $1.5M | $1.4M | ||
| Other Assets, Noncurrent | $19.2M | $18.3M | ||
| Intangible assets | $83.3M | $96.9M | ||
| Goodwill | $186.9M | $181.8M | $180.1M | |
| Total assets | $427.7M | $433.3M | ||
| Accounts payable | $4.9M | $5.7M | ||
| Accrued payroll and benefits | $19.0M | $17.9M | ||
| Unearned revenues | $14.7M | $14.7M | ||
| Other accrued expenses | $17.6M | $24.6M | ||
| Term loan, current portion | $5.6M | $3.8M | ||
| Convertible senior notes, current portion, net of debt issuance costs | $0 | $97.3M | ||
| Total current liabilities | $61.9M | $164.0M | ||
| Deferred tax liability | $20.1M | $20.2M | ||
| Other Liabilities, Noncurrent | $13.7M | $12.5M | ||
| Noncurrent portion | $61.4M | $66.9M | ||
| Revolving line of credit | $84.5M | $10.0M | ||
| Total liabilities | $241.5M | $273.5M | ||
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,931 and 5,455,421 shares, respectively | $375.3M | $358.5M | ||
| (Accumulated deficit) | -$185.7M | -$188.9M | ||
| Accumulated other comprehensive (loss) | -$3.4M | -$9.8M | ||
| Total stockholders equity | $186.2M | $159.8M | $145.4M | $393.5M |
| Total liabilities and stockholders equity | $427.7M | $433.3M | ||
| Allowance for doubtful accounts receivable | $2.6M | $1.2M | ||
| Common stock, no par value (in dollars per share) | $0 | $0 | ||
| Common stock, authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Common stock, issued (in shares) | 5.5M shares | 5.5M shares | ||
| Common stock, outstanding (in shares) | 5.5M shares | 5.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Net income (loss) | $6.7M | -$2.0M | -$254.2M |
| Depreciation of property, plant and equipment | $2.1M | $2.2M | $4.2M |
| Amortization of acquisition-related intangibles | $2.8M | $19.1M | $6.1M |
| Stock-based compensation expense | $17.9M | $13.1M | $11.9M |
| Non-cash interest expense and debt issuance cost amortization | $682.0K | $990.0K | $926.0K |
| Gain on extinguishment of convertible senior notes | $0 | -$2.9M | $0 |
| Amortization of step-up in inventory basis | $0 | $1.2M | $1.2M |
| Deferred taxes | -$1.3M | -$72.0K | -$28.4M |
| Impairment loss on goodwill and finite-lived intangible assets | $0 | $0 | $274.5M |
| Other | $577.0K | $4.9M | $629.0K |
| Accounts receivable | -$3.2M | -$2.9M | $4.9M |
| Inventories | -$4.4M | $1.2M | $2.6M |
| Prepaid expenses and other assets | $608.0K | $498.0K | $211.0K |
| Accounts payable | -$1.2M | -$388.0K | -$97.0K |
| Accrued liabilities and taxes payable | $3.5M | $9.5M | -$1.2M |
| Unearned revenues | -$255.0K | -$938.0K | -$408.0K |
| Net cash provided by operating activities | $42.8M | $46.8M | $44.1M |
| Purchases of property, plant and equipment | -$3.2M | -$4.2M | -$2.6M |
| Acquisition of customer lists | $0 | -$250.0K | $0 |
| Acquisition of businesses, net of cash acquired and holdback liabilities | $0 | $0 | -$78.7M |
| Net cash (used in) investing activities | -$3.2M | -$4.5M | -$81.3M |
| Proceeds from debt borrowings | $107.5M | $73.5M | $71.0M |
| Repurchase of convertible note debt | -$97.5M | -$71.6M | $0 |
| Other debt principal repayments | -$36.7M | -$44.3M | -$33.5M |
| GKE acquisition holdback payment | -$9.6M | $0 | $0 |
| Dividends paid | -$3.5M | -$3.5M | -$3.4M |
| Payment of tax withholding obligation on vesting of restricted stock | -$1.1M | -$887.0K | -$728.0K |
| Proceeds from the exercise of stock options | $0 | $2.6M | $358.0K |
| Other financing, net | -$966.0K | -$452.0K | -$847.0K |
| Net cash (used in) provided by financing activities | -$41.9M | -$44.5M | $32.8M |
| Net (decrease) in cash and cash equivalents | -$393.0K | -$893.0K | -$4.7M |
| Effect of exchange rate changes on cash and cash equivalents | $1.9M | $1.3M | -$359.0K |
| Income taxes | $1.9M | $5.7M | $4.6M |
| Interest | $10.0M | $11.1M | $4.6M |
No quarter-by-quarter statement was filed.
Leadership
Who has led MESA LABORATORIES INC /CO/, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerSiddhartha Kadia Apr 24, 2026 to now13
- Chief executive officerGary M. Owens Sep 1, 2017 to Apr 24, 202614
- Chief executive officerLuke R. Schmieder Feb 7, 2006 to Feb 12, 200915
- ChairLuke R. Schmieder Nov 17, 2006 to Feb 12, 200916
- PresidentSiddhartha Kadia Apr 24, 2026 to now13
- PresidentGary M. Owens Sep 1, 2017 to Apr 24, 202614
- PresidentLuke R. Schmieder Feb 7, 2006 to Apr 28, 200615
- Chief financial officerJohn Sakys V. Dec 3, 2012 to now17
- Chief operating officerGary M. Owens Mar 22, 2017 to Mar 22, 201718
Board members and other officers (19)
- Chief Accounting OfficerLyndsey Elizabeth Crennen Jun 16, 2026 to now19
- SVP of Continuous ImprovementBrian David Archbold Jun 13, 2019 to now20
- SVP Commercial OperationsGregory Dinoia Oct 24, 2018 to Jun 22, 202221
- Former DirectorLuke R. Schmieder Apr 28, 2015 to Apr 28, 201522
- Executive Vice PresidentMichael Tranmer Sep 28, 2011 to Apr 2, 201223
- VP Sales & MarketingGlenn E. Adriance Apr 4, 2008 to Mar 26, 201824
- Board memberMark Christopher Capone Feb 16, 2024 to now25
- Board memberR. Tony Tripeny Jul 11, 2022 to now26
- Board memberShiraz Shabanali Ladiwala Nov 8, 2021 to now27
- Board memberShannon Hall Jun 2, 2020 to now28
- Board memberDavid Brian Perez Jan 25, 2019 to Jun 17, 202029
- Board memberJennifer Sadie Alltoft Apr 8, 2019 to now30
- Board memberGary M. Owens Sep 1, 2017 to Sep 1, 202114
- Board memberJohn Bradley Schmieder Apr 9, 2015 to Sep 19, 202331
- Board memberDavid M. Kelly Oct 12, 2010 to Nov 9, 202132
- Board memberEvan Guillemin Feb 25, 2009 to Sep 2, 202233
- Board memberPaul D. Duke Jan 13, 2006 to May 24, 201034
- Board memberLuke R. Schmieder Feb 7, 2006 to Nov 19, 201415
- Board memberH. Stuart Campbell Mar 21, 2006 to Nov 28, 201835
Former names
- MESA LABORATORIES INC /CODec 11, 1995 to Aug 28, 20203
Timeline
Filings
325 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 182 insider forms, 29 large holders, 41 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 9, 2026SCHEDULE 13G EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 8, 20268-K EDGAR
- Aug 27, 2026144 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
The 325 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 29 such filings since October 2021, the latest 10:
- Oct 9, 2026SCHEDULE 13G
- Jul 7, 2026SCHEDULE 13G/A
- Apr 15, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Mar 13, 2026SCHEDULE 13G
- Oct 31, 2025SCHEDULE 13G/A
- Oct 2, 2025SCHEDULE 13G/A
- Apr 30, 2025SCHEDULE 13G/A
- Jan 28, 2025SCHEDULE 13G/A
- Jan 10, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARLuke R. Schmieder, Chair
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARLuke R. Schmieder, Former Director
- 23
- 24
- 25
- 26SEC EDGARR. Tony Tripeny, Board member
- 27
- 28SEC EDGARShannon Hall, Board member
- 29SEC EDGARDavid Brian Perez, Board member
- 30SEC EDGARJennifer Sadie Alltoft, Board member
- 31SEC EDGARJohn Bradley Schmieder, Board member
- 32SEC EDGARDavid M. Kelly, Board member
- 33SEC EDGAREvan Guillemin, Board member
- 34SEC EDGARPaul D. Duke, Board member
- 35SEC EDGARH. Stuart Campbell, Board member
- 36